Theravance Inc (THRX)

10.03
0.16 1.57
NASDAQ : Health Care
Prev Close 10.19
Open 10.15
Day Low/High 10.01 / 10.29
52 Wk Low/High 6.36 / 16.81
Volume 815.56K
Avg Volume 868.80K
Exchange NASDAQ
Shares Outstanding 117.43M
Market Cap 1.15B
EPS -1.50
P/E Ratio N/A
Div & Yield 1.00 (10.20%)

Theravance Inc. Q1 2010 Earnings Call Transcript

Theravance Inc. Q1 2010 Earnings Call Transcript

Pharmaceutical Short-Squeeze Opportunities

These heavily shorted pharmaceutical stocks could surge higher on any positive catalyst.

Theravance Says FDA Delays New Vitabiv Decision

Theravance says FDA wants more data before ruling on Vitabix for hospital-acquired pneumonia

Auxilium Shares Higher On FDA Drug Review: BioBuzz

Auxilium Shares Higher On FDA Drug Review: BioBuzz

FDA doesn't raise new safety issues for Auxilium's hand treatment

XOMA to Repay Goldman Loan: BioBuzz

XOMA to Repay Goldman Loan: BioBuzz

Drug company removes overhang on balance sheet

Cell Therapeutics CEO Sells Stock: BioBuzz

Cell Therapeutics CEO Sells Stock: BioBuzz

Jim Bianco unloads 30% of holdings days after investor meeting.

Biotech Calendar: Key Dates and Events

Biotech Calendar: Key Dates and Events

A quick and dirty guide to important biotech events for the busy month of September.

Biotech Calendar: Key FDA Action Dates

Biotech Calendar: Key FDA Action Dates

A quick and dirty guide to upcoming FDA approval dates for biotech drugs.

Theravance 1Q Loss Narrows On Cuts, Revenue Boost

Theravance's 1st-quarter loss narrows on cost cuts, higher revenue from partnerships

Medicines Co. to Acquire Targanta

The minimum price tag of the deal is $42 million.

FDA Declines to Approve Targanta Antibiotic

The FDA has deemed two trials for oritavancin insufficient for approval.

Health Winners & Losers: Illumina

Health Winners & Losers: Illumina

Protherics and Theravance are lower.

Tuesday's Winners & Losers: Theravance

Tuesday's Winners & Losers: Theravance

Shares dive 28% on signs of further regulatory delays for its drug telavancin.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Theravance and Obagi Medical plunge.

Wednesday's Winners & Losers: BEA Systems

Wednesday's Winners & Losers: BEA Systems

Shares soar 18.5% after Oracle successfully bids for the company.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Stereotaxis' delayed catheter gets FDA approval.

Tuesday's Late Winners & Losers

Tuesday's Late Winners & Losers

$10.7 billion wasn't enough to satisfy INTC analysts and the stock plunged.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Mylan gets FDA approval for its generic zyrtec.

FDA Panel to Review Theravance Drug

The committee soon will meet to discuss the new-drug application for skin-infection drug Telavancin.

Wednesday's Late Winners & Losers

Wednesday's Late Winners & Losers

Hoku Scientific jumped after the bell.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Merck climbs on a quarterly earnings beat.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Kyphon climbs on merger news.

Monday's Late Winners & Losers

Monday's Late Winners & Losers

Ventana Medical Systems surges on news of a hostile bid from Roche.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Adolor is plunging after halting a clinical trial for a constipation drug.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Cell Genesys jumps after its prostate cancer treatment does well in a trial.

Monday's Late Winners & Losers

Monday's Late Winners & Losers

Theravance climbs on positive results for a proposed asthma treatment.

Friday's ETF Winners & Losers

Chip-tracking funds plunge.

Theravance Drug Meets Goal

Theravance Drug Meets Goal

Still, the company's shares pull back in early trading.